Samsung Bioepis agrees on ‘SB5’ patent conflict with AbbVie
Samsung Bioepis(CEO/President Han-Seung Ko) agreed on the patent conflict about SB5(generic name: adalimumab, biosimilar referencing Humira), a biosimilar for the treatment of autoimmune disease(Anti-TNF-α).
Samsung Bioepis announced the company signed a license agreement with AbbVie, the origin...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.